iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men
NCT ID: NCT06535802
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
53 participants
OBSERVATIONAL
2023-11-20
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AI-assisted Integrated Care to Promote Colonoscopy Uptake
NCT07261059
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
NCT06682650
A Deep Learning-based System for the Bowel Preparation Evaluation Before Colonoscopy
NCT05801250
A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT03407417
Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program
NCT02419846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research.
II: Establish the acceptance and usability of the iCCaRE ViRA among 50 African American/Black men (AA/BM) at local Jacksonville sites.
OUTLINE: This is an observational study. Participants are assigned to 1 of 4 cohorts.
COHORT I: Consumer advocates attend a focus group on study.
COHORT II: Clinicians complete interviews on study.
COHORT III: CaP survivors test the virtual health intervention, complete a survey, and attend a focus group on study.
COHORT IV: Patients complete surveys and participate in the virtual health intervention on study. Patients complete survey and an interview during follow up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational cohort I
Consumer advocates attend a focus group on study.
Focus group
Attend a focus group session
Observational cohort II
Clinicians complete interviews on study.
Clinician Interviews
Participate in clinician interviews
Observational cohort III
CaP survivors test the virtual health intervention, complete a survey, and attend a focus group on study.
Focus group
Attend a focus group session
Intervention testing
Test the virtual health intervention
Survey
Complete a follow-up survey
Observational cohort V
Patients complete surveys and participate in the virtual health intervention on study. Patients complete survey and an interview during follow up.
Survey
Complete a follow-up survey
Follow-up Interview
Participate in a follow-up interview
Virtual Health Intervention
Participate in the virtual health intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Focus group
Attend a focus group session
Clinician Interviews
Participate in clinician interviews
Intervention testing
Test the virtual health intervention
Survey
Complete a follow-up survey
Follow-up Interview
Participate in a follow-up interview
Virtual Health Intervention
Participate in the virtual health intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinicians who are part of the Translational Research \& Clinical Intervention Services (TRaCIS)
* AIM 2 ALPHA TESTING: iCCaRE consumer advocates \[2 Community Advisory Board (CAB) and 1 non-CAB\]
* AIM 2 BETA TESTING-PATIENTS:
* An African American/Black male
* A patient who has been diagnosed with prostate cancer in Florida at any time in their life, and/or within the previous 6 months has had an abnormal Prostate-Specific Antigen (PSA) lab value and/or Digital Rectal Examination (DRE)
* Minimum age of 30 years old
* Consent to participating in the intervention
Exclusion Criteria
* Patients who are not African American/Black males
* Patients not diagnosed with prostate cancer in Florida at any time in their life, or within the previous 6 months has not had a normal PSA lab value and/or DRE
* Older than 80 years old
* Are not willing to consent
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Congressionally Directed Medical Research Programs
FED
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Folakemi T. Odedina, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Florida
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W81XWH2210968
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NCI-2024-05156
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC220501
Identifier Type: OTHER
Identifier Source: secondary_id
22-001412
Identifier Type: OTHER
Identifier Source: secondary_id
MC220501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.